Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study

JACC: Cardiovascular Interventions

Volumn 10, Issue 9, 2017, Pages 942-954

  Secemsky, Eric A ^a,b,c,d   Yeh, Robert W ^c,d   Kereiakes, Dean J ^e   Cutlip, Donald E ^c   Steg, P Gabriel ^f,g   Massaro, Joseph M ^c   Apruzzese, Patricia K ^c   Mauri, Laura ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e The Carl & Edyth Lindner Center for Research & Education   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

bleeding; dual antiplatelet therapy; ischemia; peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY; CORONARY STENTING; DUAL ANTIPLATELET THERAPY; FEMALE; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STENTS; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85018415695     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2017.02.013     Document Type: Article

References (26)

1. 1 Fowkes, F.G., Rudan, D., Rudan, I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (2013), 1329–1340.
2. 2 Saw, J., Bhatt, D.L., Moliterno, D.J., et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 48 (2006), 1567–1572.
3. 3 Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47 (2006), 1239–1312.
4. 4 van Werkum, J.W., Heestermans, A.A., Zomer, A.C., et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53 (2009), 1399–1409.
5. 5 Mehta, S.K., Frutkin, A.D., Lindsey, J.B., et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2 (2009), 222–229.
6. 6 Ducrocq, G., Wallace, J.S., Baron, G., et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 31 (2010), 1257–1265.
7. 7 Catalano, M., Born, G., Peto, R., Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261 (2007), 276–284.
8. 8 Hiatt, W.R., Fowkes, F.G., Heizer, G., et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376 (2017), 32–40.
9. 9 Cacoub, P.P., Bhatt, D.L., Steg, P.G., Topol, E.J., Creager, M.A., Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 30 (2009), 192–201.
10. 10 Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 69 (2017), e71–e126.
11. 11 Bittl, J.A., Baber, U., Bradley, S.M., Wijeysundera, D.N., Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol, 2016, e123–e125.
12. 12 Bonaca, M.P., Bhatt, D.L., Storey, R.F., et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 67 (2016), 2719–2728.
13. 13 Franzone, A., Piccolo, R., Gargiulo, G., et al. Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial. JAMA Cardiol 1 (2016), 795–803.
14. 14 Kereiakes, D.J., Yeh, R.W., Massaro, J.M., et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 313 (2015), 1113–1121.
15. 15 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 2014, 2155–2166.
16. 16 Cutlip, D.E., Windecker, S., Mehran, R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007), 2344–2351.
17. 17 An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 329 (1993), 673–682.
18. 18 Yeh, R.W., Secemsky, E.A., Kereiakes, D.J., et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315 (2016), 1735–1749.
19. 19 Brevetti, G., Giugliano, G., Brevetti, L., Hiatt, W.R., Inflammation in peripheral artery disease. Circulation 122 (2010), 1862–1875.
20. 20 Bhatt, D.L., Peterson, E.D., Harrington, R.A., et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 30 (2009), 1195–1202.
21. 21 Dangas, G.D., Claessen, B.E., Mehran, R., et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. J Am Coll Cardiol Intv 5 (2012), 1097–1105.
22. 22 Leunissen, T.C., Peeters Weem, S.M., Urbanus, R.T., et al. High on-treatment platelet reactivity in peripheral arterial disease: a pilot study to find the optimal test and cut off values. Eur J Vasc Endovasc Surg 52 (2016), 198–204.
23. 23 Bhatt, D.L., Fox, K.A., Hacke, W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
24. 24 Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol 68 (2016), 1082–1115.
25. 25 Mauri, L., Elmariah, S., Yeh, R.W., et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 37 (2016), 378–385.
26. 26 Food and Drug Administration. Plavix (clopidogrel): drug safety communication. Long-term treatment does not change risk of death. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm471531.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed November 6, 2015.